nn7q9a9n

Property	Value
?:abstract	This study aims to inform SARS-CoV-2 vaccine development/licensure/decision-making/implementation, using mathematical modeling, by determining key preferred vaccine product characteristics and associated population-level impacts of a vaccine eliciting long-term protection A prophylactic vaccine with efficacy against acquisition (VES) ≥70% can eliminate the infection A vaccine with VES <70% may still control the infection if it reduces infectiousness or infection duration among those vaccinated who acquire the infection, if it is supplemented with <20% reduction in contact rate, or if it is complemented with herd-immunity At VES of 50%, the number of vaccinated persons needed to avert one infection is 2 4, and the number is 25 5 to avert one severe disease case, 33 2 to avert one critical disease case, and 65 1 to avert one death The probability of a major outbreak is zero at VES ≥70% regardless of the number of virus introductions However, an increase in social contact rate among those vaccinated (behavior compensation) can undermine vaccine impact In addition to the reduction in infection acquisition, developers should assess the natural history and disease progression outcomes when evaluating vaccine impact This study aims to inform SARS-CoV-2 vaccine development/licensure/decision-making/implementation, using mathematical modeling, by determining key preferred vaccine product characteristics and associated population-level impacts of a vaccine eliciting long-term protection. A prophylactic vaccine with efficacy against acquisition (VES) ≥70% can eliminate the infection. A vaccine with VES <70% may still control the infection if it reduces infectiousness or infection duration among those vaccinated who acquire the infection, if it is supplemented with <20% reduction in contact rate, or if it is complemented with herd-immunity. At VES of 50%, the number of vaccinated persons needed to avert one infection is 2.4, and the number is 25.5 to avert one severe disease case, 33.2 to avert one critical disease case, and 65.1 to avert one death. The probability of a major outbreak is zero at VES ≥70% regardless of the number of virus introductions. However, an increase in social contact rate among those vaccinated (behavior compensation) can undermine vaccine impact. In addition to the reduction in infection acquisition, developers should assess the natural history and disease progression outcomes when evaluating vaccine impact.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/nn7q9a9n_hasAnnotation_C0042776> <https://research.tib.eu/covid-19/entity/nn7q9a9n_hasAnnotation_C1825598>
?:creator	<https://research.tib.eu/covid-19/entity/Makhoul%2C_Monia%3B_Ayoub%2C_Houssein_H%3B_Chemaitelly%2C_Hiam%3B_Seedat%2C_Shaheen%3B_Mumtaz%2C_Ghina_R%3B_Al-Omari%2C_Sarah%3B_Abu-Raddad%2C_Laith_J> <https://research.tib.eu/covid-19/entity/Makhoul%2C_Monia_Ayoub_Houssein_H.%3B_Chemaitelly%2C_Hiam_Seedat_Shaheen_Mumtaz_Ghina_R.%3B_Al-Omari%2C_Sarah_Abu-Raddad_Laith_J.>
?:journal	Vaccines
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/nn7q9a9n_HAS_C1825598_INTERACTS_WITH_C0042210> <https://research.tib.eu/covid-19/entity/nn7q9a9n_HAS_C5387588_INTERACTS_WITH_C0042210>
?:source	WHO
?:title	Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#916697 #968004
?:year	2020

Property

Value

?:abstract

This study aims to inform SARS-CoV-2 vaccine development/licensure/decision-making/implementation, using mathematical modeling, by determining key preferred vaccine product characteristics and associated population-level impacts of a vaccine eliciting long-term protection A prophylactic vaccine with efficacy against acquisition (VES) ≥70% can eliminate the infection A vaccine with VES <70% may still control the infection if it reduces infectiousness or infection duration among those vaccinated who acquire the infection, if it is supplemented with <20% reduction in contact rate, or if it is complemented with herd-immunity At VES of 50%, the number of vaccinated persons needed to avert one infection is 2 4, and the number is 25 5 to avert one severe disease case, 33 2 to avert one critical disease case, and 65 1 to avert one death The probability of a major outbreak is zero at VES ≥70% regardless of the number of virus introductions However, an increase in social contact rate among those vaccinated (behavior compensation) can undermine vaccine impact In addition to the reduction in infection acquisition, developers should assess the natural history and disease progression outcomes when evaluating vaccine impact
This study aims to inform SARS-CoV-2 vaccine development/licensure/decision-making/implementation, using mathematical modeling, by determining key preferred vaccine product characteristics and associated population-level impacts of a vaccine eliciting long-term protection. A prophylactic vaccine with efficacy against acquisition (VES) ≥70% can eliminate the infection. A vaccine with VES <70% may still control the infection if it reduces infectiousness or infection duration among those vaccinated who acquire the infection, if it is supplemented with <20% reduction in contact rate, or if it is complemented with herd-immunity. At VES of 50%, the number of vaccinated persons needed to avert one infection is 2.4, and the number is 25.5 to avert one severe disease case, 33.2 to avert one critical disease case, and 65.1 to avert one death. The probability of a major outbreak is zero at VES ≥70% regardless of the number of virus introductions. However, an increase in social contact rate among those vaccinated (behavior compensation) can undermine vaccine impact. In addition to the reduction in infection acquisition, developers should assess the natural history and disease progression outcomes when evaluating vaccine impact.

is ?:annotates of